Slingshot members are tracking this event:

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Results from the ongoing Phase IIb portion of the Viaskin MILk Efficacy and Safety (MILES) Phase I/IIb study of Viaskin Milk in IgE-mediated CMPA children and adolescents ages two to 17 are expected in the second half of 2017. A Phase II clinical trial assessing Viaskin Milk for the treatment of milk allergy-induced Eosinophilic Esophagitis (EoE) in children ages four to 17 is also ongoing in collaboration with the Children’s Hospital of Philadelphia. 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fast Track Status, Viaskin Milk, Viaskin, Cow Milk Protein Allergy, Immunoglobulin E, Viaskin Milk Efficacy And Safety, Eosinophilic Esophagitis